CA-XSOLLA
18.7.2024 14:01:34 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, announces the launch of its Mobile Software Development Kit (SDK). Whether you want to expand your payment options, go direct-to-consumer/out-of-store, or simply improve your game’s revenue potential, Xsolla Mobile SDK is the gateway to efficiently and effectively achieve these goals. This release introduces a pivotal solution for the DMA Age, empowering developers worldwide to seamlessly integrate their games on Android and iOS platforms with a global payment solution and web shop. Such integration significantly broadens the potential for mobile game monetization worldwide and unlocks new distribution channels. Game developers like Gaijin Network LTD (Crossout), Artstorm (Modern Warships), LINGCHAI (HONG KONG) LIMITED (Fantasy Tales: Sword and Magic), and ULTRAHORSE (SquadBlast) already use Xsolla SDK to monetize their games.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240718044203/en/
(Graphic: Xsolla)
The launch of the Xsolla Mobile SDK aligns with recent legislative changes worldwide, including in the European Union, particularly the Digital Markets Act (DMA), and confirmed roll-out in Japan and the UK in 2025. This shift represents a critical development in the digital marketplace, providing developers with new monetization avenues to help drive more profits by going beyond traditional app store limitations.
Xsolla’s Mobile SDK Enables Out-of-Store Transactions
Xsolla's Mobile SDK streamlines the process for developers seeking distribution solutions outside the Google Play and App Store. The SDK enables Pay Station to be the primary option for accepting payments for out-of-store transactions. Android developers can integrate it into a self-distributed APK, distributed with channeling partners supporting alternative billing methods. It is also tailored for Web Distribution and App Marketplaces for iOS notarized Apps. Moreover, it is compatible with various game engines, from Unity to Native, making it a versatile and valuable tool for developers looking to enhance their in-game payment experience. Xsolla Mobile SDK complements a Web Shop to enhance out-of-store distribution strategies.
Xsolla’s Mobile SDK Enhances In-Store Transactions with Compliance under DMA
The SDK's features include seamless integration into games already supported by the Google Play Billing Library or Apple StoreKit integrations. Xsolla's Mobile SDK provides additional functionality or replaces billing options tailored to meet Google Play (UCB) and Apple's requirements under the Digital Markets Act (DMA). With Xsolla’s Mobile SDK, games can accept payments with 700+ local payment methods in 200+ territories.
As new regulations emerge, this SDK ensures a smooth expansion to new billing models while maintaining compliance with platform requirements powered by Xsolla Pay Station in other regions.
"With the introduction of our Mobile SDK, Xsolla reaffirms its commitment to supporting mobile game developers through the evolving digital and regulatory economy," said David Stelzer, President of Xsolla. "We're here to help developers navigate the regulatory and compliance changes easily, providing them with the tools to expand their payment options, reduce commission costs, and ultimately drive greater profitability for their mobile games."
The newly released Xsolla Mobile SDK for Android has been available for developers worldwide since today, with iOS support in early access available for those operating within the European Union.
Developers can access the SDK and detailed integration guides by visiting:
Xsolla's Developer Portal
Xsolla Mobile SDK
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718044203/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom